Cytostaticahaltiger Knochenzement: Neue Aspekte in der Behandlung maligner Knochentumoren
暂无分享，去创建一个
[1] F. Reckling,et al. Changing concepts in the management of pathological and impending pathological fractures. , 1976, The Journal of trauma.
[2] R. Bender. Anti-folate resistance in leukemia: treatment with "high-dose" methotrexate and citrovorum factor. , 1975, Cancer treatment reviews.
[3] I. Goldman. Analysis of the cytotoxic determinants for methotrexate (NSC 740): a role for 'free' intracellular drug , 1975 .
[4] I. Goldman. Membrane transport of methotrexate (NSC 740) and other folate compounds: relevance to rescue protocols , 1975 .
[5] R. H. Turner,et al. The use of methylmethacrylate as an adjunct in the internal fixation of malignant neoplastic fractures. , 1972, The Journal of bone and joint surgery. American volume.
[6] J. Bertino,et al. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. , 1969, The Journal of clinical investigation.
[7] R. Bremner,et al. The management of pathological fracture of the major long bones from metastatic cancer. , 1958, The Journal of bone and joint surgery. British volume.